MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7599-7609

  Khan, Sheema ^a   Ebeling, Mara C ^b   Zaman, Mohd S ^a   Sikander, Mohammed ^a   Yallapu, Murali M ^a   Chauhan, Neeraj ^a   Yacoubian, Ashley M ^a   Behrman, Stephen W ^a   Zafar, Nadeem ^a   Kumar, Deepak ^c   Thompson, Paul A ^b   Jaggi, Meena ^a   Chauhan, Subhash C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b SANFORD RESEARCH   (United States)

^c UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

Author keywords

Diagnostics; MicroRNA; MUC13; Pancreatic cancer; Therapeutics; Tumor suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; MICRORNA 145; MUC13 PROTEIN; MUCIN; P21 ACTIVATED KINASE 1; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P53; UNCLASSIFIED DRUG; MICRORNA; MIRN145 MICRORNA, HUMAN; MUC13 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE G0 PHASE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOLECULARLY TARGETED THERAPY; MOUSE; MUC13 GENE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; CONFOCAL MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; MICE, NUDE; MICRORNAS; MICROSCOPY, CONFOCAL; MUCINS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84907485890     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2281     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010; 60(5):277-300.
2. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. International journal of cancer Journal international du cancer. 2007; 120(5):1046-1054.
3. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007; 26(30):4442-4452.
4. Dillhoff M, Liu J, Frankel W, Croce C and Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008; 12(12):2171-2176.
5. Kim VN, Han J and Siomi MC. Biogenesis of small RNAs in animals. Nature reviews Molecular cell biology. 2009; 10(2):126-139.
6. Thomson DW, Bracken CP and Goodall GJ. Experimental strategies for microRNA target identification. Nucleic acids research. 2011; 39(16):6845-6853.
7. Bardeesy N and DePinho RA. Pancreatic cancer biology and genetics. Nature reviews Cancer. 2002; 2(12):897-909.
8. Koorstra JB, Hustinx SR, Offerhaus GJ and Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008; 8(2):110-125.
9. Mimeault M, Brand RE, Sasson AA and Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas. 2005; 31(4):301-316.
10. Chauhan SC, Ebeling MC, Maher DM, Koch MD, Watanabe A, Aburatani H, Lio Y and Jaggi M. MUC13 mucin augments pancreatic tumorigenesis. Molecular cancer therapeutics. 2012; 11(1):24-33.
11. Yang XW, Zhang LJ, Huang XH, Chen LZ, Su Q, Zeng WT, Li W and Wang Q. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatology research: the official journal of the Japan Society of Hepatology. 2014; 44(5):551-559.
12. Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, Chiou GY, Chou MY and Chiou SH. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer research. 2013; 73(11):3425-3440.
13. Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y, He M, Nilubol N, Merino MJ and Kebebew E. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocrine-related cancer. 2014; 21(4):517-531.
14. Sachdeva M and Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer research. 2010; 70(1):378-387.
15. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L and Jiang BH. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic acids research. 2012; 40(2):761-774.
16. Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A and Hu J. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. Journal of experimental & clinical cancer research: CR. 2010; 29:151.
17. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A and Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PloS one. 2010; 5(1):e8836.
18. Xu N, Papagiannakopoulos T, Pan G, Thomson JA and Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009; 137(4):647-658.
19. Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C and Shen Z. MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS letters. 2014.
20. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q and Li M. Overcoming drug resistance in pancreatic cancer. Expert opinion on therapeutic targets. 2011; 15(7):817-828.
21. Khan S, Ansarullah, Kumar D, Jaggi M and Chauhan SC. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Cancer research. 2013; 73(22):6541-6547.
22. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH. Recent progress in pancreatic cancer. CA: a cancer journal for clinicians. 2013; 63(5):318-348.
23. Chauhan SC, Kumar D and Jaggi M. Mucins in ovarian cancer diagnosis and therapy. Journal of ovarian research. 2009; 2:21.
24. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nature reviews Cancer. 2009; 9(12):874-885.
25. Singh R and Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer biology & therapy. 2007; 6(4):481-486.
26. Rubinstein DB, Karmely M, Pichinuk E, Ziv R, Benhar I, Feng N, Smorodinsky NI and Wreschner DH. The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/beta junction mediates cell killing. International journal of cancer Journal international du cancer. 2009; 124(1):46-54.
27. Day JD, Digiuseppe JA, Yeo C, Lai-Goldman M, Anderson SM, Goodman SN, Kern SE and Hruban RH. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Human pathology. 1996; 27(2):119-124.
28. Chauhan SC, Vannatta K, Ebeling MC, Vinayek N, Watanabe A, Pandey KK, Bell MC, Koch MD, Aburatani H, Lio Y and Jaggi M. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer research. 2009; 69(3):765-774.
29. Khan S, Chib R, Shah BA, Wani ZA, Dhar N, Mondhe DM, Lattoo S, Jain SK, Taneja SC and Singh J. A cyano analogue of boswellic acid induces crosstalk between p53/PUMA/Bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. Eur J Pharmacol. 2011; 660(2-3):241-248.
30. Khan S, Kaur R, Shah BA, Malik F, Kumar A, Bhushan S, Jain SK, Taneja SC and Singh J. A Novel cyano derivative of 11-Keto-beta-Boswellic acid causes apoptotic death by disrupting PI3K/AKT/Hsp-90 cascade, mitochondrial integrity, and other cell survival signaling events in HL-60 cells. Molecular carcinogenesis. 2012; 51(9):679-695.
31. Yallapu MM, Othman SF, Curtis ET, Bauer NA, Chauhan N, Kumar D, Jaggi M and Chauhan SC. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine. 2012; 7:1761-1779.
32. Rah B, Amin H, Yousuf K, Khan S, Jamwal G, Mukherjee D and Goswami A. A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PloS one. 2012; 7(9):e44039.
33. Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, Hemstreet GP and Balaji KC. E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer research. 2005; 65(2):483-492.
34. Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, Yamamura S, Ueno K, Zaman MS, Singh K, Chang I, Deng G and Dahiya R. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer research. 2011; 71(7):2611-2621.